Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company is developing tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880); all three assets have completed Phase 1/1b studies and are Phase 2 ready. Proceeds from the financing are intended to accelerate development of tibulizumab, including a planned Phase 2 clinical trial in systemic sclerosis and initiation of a Phase 2 trial for hidradenitis suppurativa. The company expects the net proceeds, together with existing cash and cash equivalents, to support operations through 2027. Zura Bio also plans to use funds for general corporate purposes. The company communicated these plans in a press release noting the private placement and related securities disclosures. Zura Bio is a multi-asset clinical-stage biotechnology company led by CEO Dr. Someit Sidhu and traded on Nasdaq as ZURA. Its core pipeline includes tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168. The company is focused on demonstrating the efficacy, safety, and dosing convenience of these assets across immune and inflammatory indications. Zura Bio plans to use newly raised funds to initiate a Phase 2 clinical trial of ZB-106 in systemic sclerosis, followed by a Phase 2 trial in hidradenitis suppurativa. The company reported approximately $120 million in cash and cash equivalents. It believes this cash runway will be sufficient to fund planned operating expenses and capital requirements through 2026.

Total raised

$193M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2024